Cochrane · systematic review · CD013268
Statins for asthma
Naing, C, Ni, H · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
4
No studies
3
Included studies
NR
No studies 3 · 42.9%Ungraded 0 · 0%Very low 4 · 57.1%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Atorvastatin compared to placebo for asthma
Population: people with asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Asthma exacerbations requiring hospitalisation or a course of steroids Atorvastatin vs placebo | no estimate extracted | NR | No studies |
Health‐related quality of life Atorvastatin vs placebo | no estimate extracted | NR | No studies |
Lung function: change in morning PEF Atorvastatin vs placebo | MD 12.32 | 1 study · 60 participants | Very low Downgraded: risk of bias |
Lung function: change in FEV1 (pre) Atorvastatin vs placebo | MD 0.13 | 1 study · 60 participants | Very low Downgraded: risk of bias |
Lung function: change in FEV1 (post) Atorvastatin vs placebo | MD 0.11 | 1 study · 60 participants | Very low Downgraded: risk of bias |
Serious adverse events or adverse events Atorvastatin vs placebo | no estimate extracted | NR | No studies |
Asthma control: change in ACQ Atorvastatin vs placebo | MD 0.41 | 1 study · 60 participants | Very low Downgraded: risk of bias |